Ruyi Tang
Ruyi Tang, CFA is Director at Selesta, a unique boutique healthcare and life science firm dedicated to serving Asia’s emerging entrepreneurs and businesses.
Ruyi has 10 years of experience in China healthcare equity research in investment banks. Her previous experience includes healthcare equity research at Jefferies, China Renaissance and BOCI, etc. Ruyi has a BS in Finance from Shanghai Jiaotong University and an MS in Mathematical Finance from Boston University.
Ruyi Tang, CFA is Director at Selesta, a unique boutique healthcare and life science firm dedicated to serving Asia’s emerging entrepreneurs and businesses.
Ruyi has 10 years of experience in China healthcare equity research in investment banks. Her previous experience includes healthcare equity research at Jefferies, China Renaissance and BOCI, etc. Ruyi has a BS in Finance from Shanghai Jiaotong University and an MS in Mathematical Finance from Boston University.
Articles: Ruyi Tang
Asia Healthcare Weekly: 7th April 2025
APAC / This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to Merck for USD 500mn, and…
Asia Healthcare Weekly: 31st March 2025
APAC / This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to Bayer, AbbVie accusing Genmab of ADC trade secret theft on ADC technology used by ProfoundBio, and Singapore’s A*STAR investing in TW-based HoneyBear to accelerate ARC…
Latest Report
